We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+10.86%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$5.06B
AUM Growth
–
Cap. Flow
+$4.02B
Cap. Flow %
79.47%
Top 10 Hldgs %
79.91%
Holding
75
New
67
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$880M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$674M
3
GHDX
Genomic Health, Inc.
GHDX
+$448M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$420M
5
INCY icon
Incyte
INCY
+$324M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 48.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
51
Ligand Pharmaceuticals
LGND
$5.71B
$2.75M 0.05%
+117,660
New +$2.12M
WINT
52
DELISTED
Windtree Therapeutics Inc
WINT
$2.31M 0.05%
+108,473
New +$2.67M
ENTA icon
53
Enanta Pharmaceuticals
ENTA
$392M
$2.21M 0.04%
+125,000
New +$2.44M
ARQL
54
DELISTED
Arqule Inc
ARQL
$2.04M 0.04%
+879,805
New +$2.37M
CYTR
55
DELISTED
CytRx Corp
CYTR
$2M 0.04%
+166,667
New +$2.46M
RCPT
56
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1.99M 0.04%
+100,000
New +$1.69M
GERN icon
57
Geron
GERN
$977M
$1.5M 0.03%
+1,058,000
New +$1.15M
FOLD
58
DELISTED
Amicus Therapeutics
FOLD
$1.2M 0.02%
+515,072
New +$1.58M
TSRO
59
DELISTED
TESARO, Inc.
TSRO
$1.02M 0.02%
+31,218
New +$964K
ALBO
60
DELISTED
Albireo Pharma Inc
ALBO
$961K 0.02%
+7,663
New +$797K
OSUR icon
61
OraSure Technologies
OSUR
$268M
$945K 0.02%
+243,467
New +$1.09M
APEN
62
DELISTED
Apollo Endosurgery, Inc.
APEN
$880K 0.02%
+2,597
New +$976K
EPZM
63
DELISTED
Epizyme, Inc
EPZM
$563K 0.01%
+20,000
New +$514K
TCRT icon
64
Alaunos Therapeutics
TCRT
$4.47M
$536K 0.01%
+1,695
New +$471K
CBST
65
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$241K ﹤0.01%
+5,000
New +$246K
ARDM
66
DELISTED
ARADIGM CORPORATION
ARDM
$16K ﹤0.01%
+100,000
New +$16K
1 2
3

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Julian Baker, which disclosed 75 positions worth $5.06B. Its ten largest holdings account for 80% of the portfolio.

Its largest position is PHARMACYCLICS INC: 10,771,138 shares worth $856M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets.

  • Julian Baker's largest Q2 2013 buy was PHARMACYCLICS INC: 10,771,138 shares worth $856M.
  • Julian Baker's ten largest holdings make up 80% of its $5.06B portfolio in Q2 2013.
  • Julian Baker disclosed 75 positions in Q2 2013, its first 13F filing on record.

Based on Baker Bros. Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.